フィラナ・セラピューティクス
Filana Therapeutics, Inc.
Filana Therapeutics, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.21 | $0 | — |
| 2025 Q4 | -0.26 | $0 | -$10M |
| 2025 Q3 | -0.22 | $0 | -$6M |
| 2025 Q2 | -0.92 | $0 | — |
| 2025 Q1 | -0.48 | $0 | -$11M |
| 2024 Q4 | -0.57 | $0 | -$61M |
| 2024 Q3 |
| -0.58 |
| $0 |
| -$18M |